Selling the firm's brands to retailers requires knowledge of the products, but as recently as two years ago, the average tenure of salespersons in P&G's health care category's was less than 12 months, says CEO David Taylor.
Investments to “improve category mastery”in Procter & Gamble Co.'s North American consumer health product sales force helped drive6% growth to $1.8bn in the segment's sales, with oral care advertising and product innovation also helping.
During P&G's fiscal 2016 fourth-quarter earnings briefing with analysts on Aug. 3, President and CEO David Taylor noted that selling...
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
